2Gore JL, Kwan L, Lee SP, et al. Survivorship beyond convalescence : 48-month quality-of-life outcomes after treatment for localized prostate cancer. J Natl Cancer Inst, 2009, 101 (12) : 888- 892.
3Sylvester JE, Grimm PD, Blasko JC, et al. 15-year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int J Radiat Oncol Biol Phys, 2007, 67 ( 1 ) : 57-64.
4Arvold ND, Chen MH, Moul JW, et al. Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease. J Urol, 2011, 186( 1 ): 91-96.
5Blasko JC, Grimm PD, Sylvester JE, et al. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys, 2000, 46(4) : 839-850.
10Shirvani SM, Kudehadker R J, Bruno TL, et al. Impact of urinary catheterization on dosimetry after prostate implant brachytherapy with palladium- 103 or iodine- 125. Brachytherapy, 2011, 10 (4) : 269- 274.
3Figg WD, Franks ME, Venzon D, et al. Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancer. World J Urol, 2004, 22 ( 6 ) : 425- 430.
4D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer, 2002, 95 (2) : 281- 286.
5Freedland SJ, Presti JC Jr, Kane CJ, et al. Do younger men have better biochemical outcomes after radical prostatectomy? Urology, 2004, 63(3) : 518-522.
6Herold DM, Hanlon AL, Movsas B, et al. Age-related prostate cancer metastases. Urology, 1998, 51 (6): 985-990.
7Benaim EA, Pace CM, Roehrborn CG. Gleason score predicts androgen independent progression after androgen deprivation the-rapy. Eur Urol, 2002, 42(1) : 12-17.
8Pellizzon AC, Salvajoli J, Novaes P, et al. Updated results of high-dose rate brachytherapy and external beam radiotherapy for locally and locally advanced prostate cancer using the RTOG-ASTRO Phoenix definition. Int Braz J Urol, 2008, 34 ( 3 ) : 293- 301.
9Klotz L, Schellhammer P, Carroll K. A re-assessment of the role of combined androgen blockade for advanced prostate cancer. BJU Int, 2004, 93(9) : 1177-1182.
10Kitagawa Y, Koshida K, Mizokami A, et al. Pathological effects of neoadjuvant hormonal therapy help predict progression of prostate cancer after radical prostatectomy. Int J Urol, 2003, 10(7) : 377-382.
